Noxopharm的TBK1抑制剂idronoxil I期临床试验显示新冠肺炎患者有抗炎应答

2021-08-26 国际文传 网络

继I期临床取得阳性结果后,临床试验向全球扩展

澳大利亚临床阶段药物开发公司Noxopharm (ASX:NOX)已发布其NOXCOVID I期临床试验的初步头条数据,该试验旨在研究TBK1(TANK结合激酶1)抑制剂idronoxil (Veyonda®)是否适合作为一种抗炎药用于中度新冠肺炎疾病患者。基于初步的阳性结果,Noxopharm已开始讨论将Veyonda加入一项全球临床试验,该试验旨在确定新冠肺炎疾病的有效抗炎治疗药物。

阻断型TBK1有两大重要意义:(i)能阻断对RNA病毒(例如冠状病毒和流感病毒)的功能失调的免疫应答;(ii)有望避免标准抗炎药(例如泼尼松和地塞米松)的不良免疫抑制效应,这些效应可能延缓病毒清除,增加继发感染的风险。

Noxopharm首席执行官兼董事总经理Graham Kelly表示:“NOXCOVID I期临床试验结果非常鼓舞人心,Veyonda在其中发挥了重要作用,因为很大比例的患者正在经历炎症加剧。该试验中未见重大安全问题,38例伴中度呼吸系统疾病的住院患者中有37例康复。”

莫纳什大学和哈德逊研究所儿科免疫学教授、莫纳什儿童医院儿科医生Marcel Nold, M.D.表示:“根据目前已知的情况,Veyonda的特性使其有望填补我们新冠肺炎治疗药物阵容中的空白。患者能自行服药,从而实现居家用药。其作用机制能治疗中度新冠肺炎患者,更重要的是,Veyonda还可有效抗击许多其他病毒。Veyonda为Noxopharm带来了一个令人激动的、近在咫尺的机会。”

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1653200, encodeId=997316532004d, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Thu Jan 13 00:12:40 CST 2022, time=2022-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852738, encodeId=93c91852e387a, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri Jul 22 19:12:40 CST 2022, time=2022-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2024051, encodeId=2d1b202405194, content=<a href='/topic/show?id=5fa61e182a9' target=_blank style='color:#2F92EE;'>#TBK1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17182, encryptionId=5fa61e182a9, topicName=TBK1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Mon Mar 28 14:12:40 CST 2022, time=2022-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787738, encodeId=a6ff1e8773840, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sun Oct 17 14:12:40 CST 2021, time=2021-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2088867, encodeId=8a4f208886e8c, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10189, encryptionId=53961018913, topicName=I期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Thu Apr 14 16:12:40 CST 2022, time=2022-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1029903, encodeId=6b6610299039b, content=新冠肺炎,疫情何时才能消失, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=公卫新人, createdTime=Thu Aug 26 17:12:40 CST 2021, time=2021-08-26, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1653200, encodeId=997316532004d, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Thu Jan 13 00:12:40 CST 2022, time=2022-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852738, encodeId=93c91852e387a, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri Jul 22 19:12:40 CST 2022, time=2022-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2024051, encodeId=2d1b202405194, content=<a href='/topic/show?id=5fa61e182a9' target=_blank style='color:#2F92EE;'>#TBK1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17182, encryptionId=5fa61e182a9, topicName=TBK1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Mon Mar 28 14:12:40 CST 2022, time=2022-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787738, encodeId=a6ff1e8773840, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sun Oct 17 14:12:40 CST 2021, time=2021-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2088867, encodeId=8a4f208886e8c, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10189, encryptionId=53961018913, topicName=I期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Thu Apr 14 16:12:40 CST 2022, time=2022-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1029903, encodeId=6b6610299039b, content=新冠肺炎,疫情何时才能消失, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=公卫新人, createdTime=Thu Aug 26 17:12:40 CST 2021, time=2021-08-26, status=1, ipAttribution=)]
    2022-07-22 jklm09
  3. [GetPortalCommentsPageByObjectIdResponse(id=1653200, encodeId=997316532004d, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Thu Jan 13 00:12:40 CST 2022, time=2022-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852738, encodeId=93c91852e387a, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri Jul 22 19:12:40 CST 2022, time=2022-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2024051, encodeId=2d1b202405194, content=<a href='/topic/show?id=5fa61e182a9' target=_blank style='color:#2F92EE;'>#TBK1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17182, encryptionId=5fa61e182a9, topicName=TBK1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Mon Mar 28 14:12:40 CST 2022, time=2022-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787738, encodeId=a6ff1e8773840, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sun Oct 17 14:12:40 CST 2021, time=2021-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2088867, encodeId=8a4f208886e8c, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10189, encryptionId=53961018913, topicName=I期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Thu Apr 14 16:12:40 CST 2022, time=2022-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1029903, encodeId=6b6610299039b, content=新冠肺炎,疫情何时才能消失, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=公卫新人, createdTime=Thu Aug 26 17:12:40 CST 2021, time=2021-08-26, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1653200, encodeId=997316532004d, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Thu Jan 13 00:12:40 CST 2022, time=2022-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852738, encodeId=93c91852e387a, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri Jul 22 19:12:40 CST 2022, time=2022-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2024051, encodeId=2d1b202405194, content=<a href='/topic/show?id=5fa61e182a9' target=_blank style='color:#2F92EE;'>#TBK1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17182, encryptionId=5fa61e182a9, topicName=TBK1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Mon Mar 28 14:12:40 CST 2022, time=2022-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787738, encodeId=a6ff1e8773840, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sun Oct 17 14:12:40 CST 2021, time=2021-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2088867, encodeId=8a4f208886e8c, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10189, encryptionId=53961018913, topicName=I期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Thu Apr 14 16:12:40 CST 2022, time=2022-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1029903, encodeId=6b6610299039b, content=新冠肺炎,疫情何时才能消失, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=公卫新人, createdTime=Thu Aug 26 17:12:40 CST 2021, time=2021-08-26, status=1, ipAttribution=)]
    2021-10-17 jj000001
  5. [GetPortalCommentsPageByObjectIdResponse(id=1653200, encodeId=997316532004d, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Thu Jan 13 00:12:40 CST 2022, time=2022-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852738, encodeId=93c91852e387a, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri Jul 22 19:12:40 CST 2022, time=2022-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2024051, encodeId=2d1b202405194, content=<a href='/topic/show?id=5fa61e182a9' target=_blank style='color:#2F92EE;'>#TBK1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17182, encryptionId=5fa61e182a9, topicName=TBK1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Mon Mar 28 14:12:40 CST 2022, time=2022-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787738, encodeId=a6ff1e8773840, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sun Oct 17 14:12:40 CST 2021, time=2021-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2088867, encodeId=8a4f208886e8c, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10189, encryptionId=53961018913, topicName=I期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Thu Apr 14 16:12:40 CST 2022, time=2022-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1029903, encodeId=6b6610299039b, content=新冠肺炎,疫情何时才能消失, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=公卫新人, createdTime=Thu Aug 26 17:12:40 CST 2021, time=2021-08-26, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1653200, encodeId=997316532004d, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Thu Jan 13 00:12:40 CST 2022, time=2022-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852738, encodeId=93c91852e387a, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri Jul 22 19:12:40 CST 2022, time=2022-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2024051, encodeId=2d1b202405194, content=<a href='/topic/show?id=5fa61e182a9' target=_blank style='color:#2F92EE;'>#TBK1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17182, encryptionId=5fa61e182a9, topicName=TBK1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Mon Mar 28 14:12:40 CST 2022, time=2022-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787738, encodeId=a6ff1e8773840, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sun Oct 17 14:12:40 CST 2021, time=2021-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2088867, encodeId=8a4f208886e8c, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10189, encryptionId=53961018913, topicName=I期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Thu Apr 14 16:12:40 CST 2022, time=2022-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1029903, encodeId=6b6610299039b, content=新冠肺炎,疫情何时才能消失, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=公卫新人, createdTime=Thu Aug 26 17:12:40 CST 2021, time=2021-08-26, status=1, ipAttribution=)]
    2021-08-26 公卫新人

    新冠肺炎,疫情何时才能消失

    0

相关资讯

临床试验中日期不完整的填补策略

临床试验中,日期采集很多,如随访点,不良反应记录日期,各个指标记录日期。但是常会出现日期不完整的现象。

辉瑞对12岁以下儿童展开新冠疫苗临床试验

据NEXSTAR、CNBC等外媒报道,美国辉瑞制药公司(Pfizer)近日宣布,已开始对12岁以下儿童展开新冠疫苗临床试验。截至目前,尚未有在儿童及婴儿中使用的新冠疫苗批准上市。

NEJM: 临床试验主要结局是阴性的,接下来怎么办?

2020年4月29日,国际顶级医学期刊《柳叶刀》在线发表了由国家呼吸疾病临床研究中心等多家单位实施的在中国武汉进行的新冠肺炎(COVID-19)抗病毒药物瑞德西韦全球首个随机、双盲、安慰剂对照、多中心

Lancet Neurology:onasmonogene abeparvovec治疗有症状的婴儿型脊髓性肌萎缩症患者的3期临床试验

脊髓性肌萎缩症是一种常染色体隐性遗传的神经疾病,临床表现差异较大。根据患者起病年龄和临床病程,由重到轻分为4型。大多数受影响的人表现为一种严重的婴儿型,称为脊髓性肌萎缩症1型。

JAHA:不能参加强化降压临床试验个体的人群特征

强化血压治疗试验并不能代表许多心血管风险较低的年轻成年人和当前推荐更低目标血压的伴有多种合并症老年人。

ANANDA Scientific和纽约大学格罗斯曼医学院宣布,评估Liquid Structure™大麻二酚(CBD)治疗创伤后应激障碍(PTSD)的临床试验的首例患者已入组

生物技术制药公司ANANDA和纽约大学格罗斯曼医学院今天宣布,评估在研药物Nantheia™ A1002N5S治疗创伤后应激障碍和PTSD合并创伤性脑损伤患者PTSD症状和神经认知障碍的临床试验已入组

拓展阅读

Hip Pelvis:新冠肺炎疫情对髋部骨折患者康复的影响

大流行疫情对住院护理医院的老年髋部骨折患者术后活动的恢复有不利影响,在完全限制家属进入以防止感染的情况下。

Critical Care Medicine:巴瑞替尼与c治疗重症新冠肺炎的疗效与不良反应

我们对重症新冠肺炎住院患者进行的倾向性得分匹配的回顾性观察研究显示,与托珠单抗相比,巴瑞替尼的病死率没有差异,但不良反应显著减少。

Critical Care Medicine:肾素-血管紧张素系统途径疗法与改善新冠肺炎男性住院患者预后相关

男性使用ARB与较低的机械通气和血管活性药物的使用率有关,而在女性中没有观察到该现象。RAS系统失调的性别差异可能导致COVID-19患者预后和对ARB药物反应性的性别差异。

2023年度巨献:中国中药领域十大医学研究出炉

2023年梅斯年终巨献:中国重磅级医学研究成果解读!

重磅!钟南山团队最新发表,连花清瘟的双盲、随机对照临床试验的结果出炉!

《病毒学》:与对照组相比,连花清瘟能够加速缓解多种临床症状,包括鼻塞、喉咙痛、咳嗽、发烧等等,从而促进轻至中度新冠肺炎患者的恢复。且两组安全性相当。

Lancet Respir Med:英国新冠肺炎住院后的多器官MRI发现

因新冠肺炎住院后,人们中期面临多器官异常的风险,本文发现强调了积极主动的多学科护理途径的必要性,并有可能进行成像来指导监测频率和治疗分层。

FDA指南:数据监测委员会在临床试验中的使用

美国食品和药品监督管理局(FDA,Food and Drug Administration) · 2024-02-13

阿达木单抗注射液生物类似药临床试验指导原则

国家药品监督管理局药品审评中心(CDE) · 2020-08-03

临床试验受试者补偿兑付平台实践专家共识

上海市精神卫生中心 · 2023-12-25

FDA指南:在FDA监管的医疗产品的临床试验和临床研究中收集种族和民族数据

美国食品和药品监督管理局(FDA,Food and Drug Administration) · 2024-01-29

临床试验纸质源文件受控管理专家共识

复旦大学附属华山医院 · 2023-12-15